Alice Melao,  —

Catalyst Pharmaceuticals has taken the first step to expand its commercial territory to cover Japan and get Firdapse (amifampridine phosphate) approved as a treatment for Lambert-Eaton myasthenic syndrome (LEMS) in the country. The company announced it has amended the original license agreement of Firdapse, which was signed…

Patients who have Lambert-Eaton myasthenic syndrome (LEMS) associated with small cell lung cancer (SCLC) seem to have better long-term survival than cancer patients without this neurologic syndrome, a study shows. The study, “Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome,” was published in the journal Neurology.

Use of the immunotherapy alemtuzumab can promote the development of Lambert-Eaton myasthenic syndrome (LEMS), a rare case study in a patient with relapsing-remitting multiple sclerosis suggests. The study, “Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration,” was published in the journal Multiple Sclerosis and Related Disorders.

Lambert-Eaton myasthenic syndrome (LEMS) that’s not associated with cancer is associated with early onset of the disease, but it does not have an impact on the long-term survival of patients, according to researchers. These findings are from a large-scale study conducted by Duke Myasthenia Gravis Clinic researchers. The team…

Lambert-Eaton myasthenic syndrome (LEMS) has been linked to cancer, with more than half of LEMS patients having cancer, most of them a small cell lung cancer (SCLC). Researchers have now reported a rare case of LEMS associated with two types of cancer in a patient: breast cancer and small cell…

University of Missouri researchers presented a rare case of Lambert–Eaton myasthenic syndrome (LEMS) that initially showed eye muscle weakness as a primary symptom in a 59-year-old woman, according to a report in the journal Cureus. Myasthenia gravis and LEMS are two autoimmune disorders that share a…